ASH Summit on Immunotherapies for Hematologic Diseases

Omni Shoreham Hotel, Washington, DC

Why is the success of immunotherapies and other targeted therapies such as gene therapy so variable within different patient populations? How can we improve these targeted therapies for widespread use in patients with hematologic diseases? Help answer these questions and more at the ASH Summit on Immunotherapies for Hematologic Diseases.

This in-person Summit is a unique meeting of the minds, bringing together  academic, medical, industry, and federal regulatory communities to address the obstacles in immunotherapy treatment development for classical and malignant hematologic conditions. Whether you’re an established academic investigator, trainee, practicing clinician, industry researcher, or federal regulator, you won’t want to miss this unique opportunity to share ideas! Through participation in this meeting, attendees will be able to:

  • Discuss fundamental advances in basic immunology that provide the foundation for immune therapies and their application
  • Gain insights into critical limitations of immunotherapies and gene therapy including associated adverse events
  • Examine cellular and molecular mechanisms involved in resistance and relapse associated with these therapies
  • Review new immunotherapy targets
  • Discuss the application of CRISPR gene editing in the development of targeted therapies
  • Analyze cell manufacturing considerations
  • Learn about the application of immunotherapies for the treatment of both classical hematologic and malignant diseases


The ASH Summit on Immunotherapies for Hematologic Diseases is designed to provide a wide set of learning and networking opportunities for experts in hematology, including:

  • Laboratory-based scientists
  • Translational and clinical researchers
  • Practitioners interested in the application of immunotherapies
  • Young investigators (trainees)
  • Cellular therapy, gene therapy, biopharmaceutical, and life sciences industry experts
  • Regulatory scientists